How many employees does Nektar Therapeutics have?

Nektar Therapeutics reported 63 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 13, 2026. That is up 3.3% from a year earlier.

What is Nektar Therapeutics's revenue per employee?

Nektar Therapeutics brought in $55.2M of revenue in fiscal Dec 2025, which is $877K per employee. That ranks 38 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Nektar Therapeutics employees and revenue per employee

NKTR · Biotechnology · $1.18B market cap

Nektar Therapeutics had 63 employees at the end of fiscal Dec 2025, up 3.3% from a year earlier. Revenue for the year was $55.2M, down 43.9% from a year earlier, or $877K per employee. Revenue fell while headcount grew.

Employees

+3.3% YoY

Revenue

$55.2M

-43.9% YoY

Revenue / employee

$877K

Peer median $459K

Rank in industry

38 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

NKTR employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	63	$55.2M	$877K	+3.3%	-43.9%
Dec 2024	61	$98.4M	$1.61M	-55.5%	+9.2%
Dec 2023	137	$90.1M	$658K	-36.6%	-2.1%
Dec 2022	216	$92.1M	$426K	-70.8%	-9.7%
Dec 2021	740	$102M	$138K	+3.1%	-33.4%
Dec 2020	718	$153M	$213K	-0.7%	+33.4%
Dec 2019	723	$115M	$159K	+17.0%	-90.4%
Dec 2018	618	$1.19B	$1.93M	+21.4%	+287.8%
Dec 2017	509	$308M	$605K	+8.8%	+86.0%
Dec 2016	468	$165M	$353K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Nektar Therapeutics against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
NKTR Nektar Therapeutics	63	$55.2M	$877K	Hiring into decline
ARCT Arcturus Therapeutics Holdings Inc.	106	$67.2M	$634K	Contracting
ENTA Enanta Pharmaceuticals, Inc.	120	$65.3M	$544K	Contracting
TNGX Tango Therapeutics, Inc.	137	$62.4M	$455K	Leaner
SEPN Septerna Inc	130	$46.0M	$353K	Efficient growth
PTGX Protagonist Therapeutics, Inc.	132	$46.0M	$349K	Hiring into decline
NUVB Nuvation Bio Inc.	298	$62.9M	$211K	Efficient growth
OCUL Ocular Therapeutix, Inc.	325	$51.8M	$159K	Hiring into decline
AGIO Agios Pharmaceuticals, Inc.	539	$54.0M	$100K	Efficient growth

Every Healthcare company

Questions about Nektar Therapeutics

How many employees does Nektar Therapeutics have?: Nektar Therapeutics reported 63 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 13, 2026. That is up 3.3% from a year earlier.
What is Nektar Therapeutics's revenue per employee?: Nektar Therapeutics brought in $55.2M of revenue in fiscal Dec 2025, which is $877K per employee. That ranks 38 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare NKTR with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Nektar Therapeutics's annual reports (Form 10-K), latest filed March 13, 2026. This is data, not a recommendation to buy or sell NKTR.